Completed PHASE2 INTERVENTIONAL 1-arm NCT01256060

Intranasal Oxytocin for the Treatment of Children and Adolescents With ASD (OXY)

Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)

Sponsor: Evdokia Anagnostou

Updated 6 times since 2017 Last updated: Jul 12, 2016 Started: Nov 30, 2010 Primary completion: Mar 31, 2013 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01256060, this PHASE2 trial focuses on Autism Spectrum Disorder and remains completed. Sponsored by Evdokia Anagnostou, it has been updated 6 times since 2010, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Evdokia Anagnostou
Holland Bloorview Kids Rehabilitation Hospital
The Hospital for Sick Children
University of Illinois at Chicago

Data source: Anagnostou, Evdokia, M.D.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada